Abstract
Treatment of psoriasis monoclonal antibodies was first used in clinical experiments in the early 90s century, but in its current form we can find it in registration trials since 2004. Since then, about this new targeted Therapy has published a number of data based on the results of the international randomized clinical trials, national registries, post-marketing reports, clinical trials and descriptions of individual cases.
In recent years, they were also issued various national and international best practices for biological treatment of psoriasis, some of them have been revised and added to, for example, In 2011, German and American. In the Czech Republic they were published consensus best practices Czech Dermatology and Venereology of CzMA, z. s., biologics to treat psoriasis in 2006 and 2012.
In general, agree that the biological treatment is given of its expense suitable only for severe disease who have failed standard systemic therapy.